The rise of GLP-1 drugs: Why the beverage industry’s biggest challenge isn’t reformulation – it’s relevance

Over the past decade, the beverage aisle has been reshaped by health-driven reformulation. What started as niche preferences – low-fat, low-alcohol, zero-sugar, gut-friendly – evolved into mainstream expectations, pushing brands to diversify, premiumise and reformulate. Health shifted from a sub-category to center-stage. 

However, the rise of GLP-1 weight-loss drugs marks a fundamentally different inflection point. 

Unlike previous health trends that encouraged consumers to make ‘better’ choices, GLP-1 medications reduce appetite itself. They do not simply steer shoppers toward lower-calorie drinks – they suppress the very impulse to consume. This is not a reformulation challenge. It is a demand challenge. 

By the end of 2024, the US GLP-1 market reached approximately $50 billion and is forecast to double by the end of the decade. The downstream implications for food and drink are already material. By 2030, it is estimated that 35% of food and beverage sales could be influenced by GLP-1 users. In the US, around 1 in 8 adults report having taken weight-loss medication in the past year. While UK uptake remains lower at approximately 2.9%, penetration is rising rapidly as access improves and social normalization increases. As with most transformative health movements, adoption is unlikely to remain geographically contained. 

This raises an uncomfortable question for an industry built on frequency, occasion and impulse: what happens when appetite declines at scale? 

For beverage brands, the strategic challenge extends far beyond ‘healthier’ formulations. The real question is how to drive growth when consumption occasions shrink, when habitual purchases soften and when consumers don’t just want fewer calories – they want fewer drinks. 

GLP-1s signal not just a behavioral shift, but a psychological one. Hunger cues change, impulse purchases decline and social and habitual drinking occasions evolve. The impact reaches beyond portion size to fundamentally reshape how, when and why people drink at all. 

In recent conversations with our partners at Pilot Lite, one point came through clearly: many CPG organizations understand the headline risk, but far fewer have changed the operating rhythm in response. In an increasingly complex and changing market, the advantage is not simply a strong strategy, but rather being able to learn fast and reduce the timeframe between consumer insight, decision-making, supply planning and in-market execution. The brands that win will not be those that resist these shifts or attempt incremental reformulation. They will be those that understand the behavioral mechanics underpinning it – and build the organizational and supply chain muscle to act on them. 

So, what do we already know about these changing consumer behaviors? And more importantly, what must brands do now to stay ahead? 

Insight one: From impulse consumption to intentional drinking

GLP-1 drugs have a far greater impact than simply suppressing appetites – they reshape consumer psychology. Consumption is shifting from reactive and impulse-led to deliberate and goal-oriented. 

GLP-1 users consistently report a decline in ‘grab it because it’s there’ behavior. Beverage purchases become more purposeful: hydration, protein intake, digestive support, lower sugar, lower alcohol etc. Alcohol offers a clear example. Clinical research indicates GLP-1 users reduce alcohol consumption by roughly 30–40%. As GLP-1 adoption rises, this behavioral moderation represents a structural risk to the alcohol sector; in markets such as the UK, some beer and spirits brands are already reporting early signs of impact. 

Broader spending data also reflects this moderation. Research from Cornell University in 2024 found spending on coffee and fast-food beverages declined by approximately 8% among GLP-1 households. This is not category abandonment – it is behavioral change. 

The shift has a biological basis. GLP-1 medications act on brain regions linked to reward processing and impulse control, dampening cravings and reducing the pull of instant gratification. The result is not just smaller baskets, but more intentional ones. 

GLP-1 users are redefining the purpose of beverages. Consumption must increasingly justify itself as functional fuel, not just taste, treat or habit. 

In conversations with Pilot Lite, they pointed to Huel as a brand that benefits from a GLP-1-era logic: consumers may not feel like eating, but they still need nutrients. Danone’s recent agreement to acquire Huel, extending its portfolio into functional nutrition, suggests that large corporations are beginning to value brands built around convenience, nutrient density and complete fueling, rather than traditional taste and enjoyment alone.  

This does not mean taste and pleasure disappear, but they do become less decisive. Early evidence has suggested that GLP-1 usage can even alter taste preferences – in some cases permanently. If appetite and cravings are muted, the old hierarchy of flavor-first indulgence weakens.  

Insight two: From brand loyalty to trust

As behavior becomes more intentional, brand relationships evolve. 

GLP-1 users are paying closer attention to what is inside their drinks: sugar load, protein levels, alcohol strength, artificial ingredients, carbonation and acidity. This is not simply heightened health-consciousness – it is a form of risk management. GLP-1 medications are associated with side effects including nausea, bloating, reflux, constipation and gastrointestinal discomfort – with around 40% of users reporting some form of adverse effect. GLP-1 users are increasingly conscious that consumption carries consequence. 

The decision framework shifts from ‘I like this brand’ to ‘can I rely on this brand not to make me feel unwell?’ 

Research supports this more evaluative mindset. A 2025 study by Acosta Group found nearly 80% of GLP-1 users conduct product and health research to support their weight-loss journey, with 36% consulting a nutritionist. These consumers are actively interrogating ingredients and functional claims rather than defaulting to habitual favorites. 

In this environment, reassurance overtakes recognition. Brand loyalty is not dead, but it manifests differently: consumers are more fickle, more informed and quicker to switch when a brand no longer feels culturally or physically compatible. Ingredient transparency, digestive tolerance and functional alignment matter more than heritage branding. Trust – defined by clarity, simplicity and credibility – becomes the new competitive advantage. 

Insight three: Retail economics shift

The third shift is structural. 

GLP-1 medications dampen dopamine signalling in the brain’s reward pathways. Consumers do not just consume less – they want less. This directly challenges the commercial architecture of beverage retail. 

Volume-led growth models assume appetite elasticity – that shoppers can be nudged into buying more than planned. Multi-buy promotions, upsizing, end-of-aisle displays and checkout fridges are all designed to stimulate incremental desire. 

But when appetite capacity declines and dopamine response is blunted, that elasticity weakens. ‘Buy-one-get-one-free’ offers lose power when a second unit feels excessive. High-impact displays generate visibility, but not urgency. The financial modeling that underpins bundling and promotional depth becomes harder to sustain. 

GLP-1 drugs do not merely trim demand at the margins – they erode the behavioral economics that have supported decades of impulse-driven volume growth. In a lower-reward, lower-frequency environment, brands must compete on relevance, context and function rather than engineered excitement. 

Insight four: The power of supply chains

The fourth shift is operational: supply chain agility becomes a competitive advantage. Changes in consumption – from smaller portions and product formulations – require rapid shifts in manufacturing, packaging and distribution. 

As Pilot Lite shared, many large organizations do not have the flexibility and agility to test new products, quickly access alternative manufacturing and adjust based on ever-changing consumer preferences. The implication is not just to rethink growth models, but a need to rethink the speed at which those models can be tested and adapted – and whether the infrastructure, governance and partner ecosystem exist to support them. 

This is where the speed of translating insight into decisions becomes critical. In the old model, consumer insights, marketing, sales and demand planning could cooperate sequentially. In the current environment, they need to operate as an integrated system: spotting demand shifts, making decisions, testing in-market and adapting supply in a much tighter loop.  

So what? Three strategic recommendations for beverage brands

If GLP-1 rewires consumption logic, brands must respond on three fronts: economics, credibility and context, all whilst ensuring a timely operating speed.  

1. Rebuild the growth model beyond volume

GLP-1 drugs undermine the assumption of appetite elasticity, resulting in fewer impulse purchases, less incremental units and lower tolerance for excess. 

For decades beverage growth has relied on frequency expansion, upsizing, bundling and multi-pack promotions. In this way, the model relied upon being able to persuade consumers in the moment. As consumption becomes increasingly intentional and frequency declines, this growth equation changes from volume per basket to probability of being in the basket. 

The strategy now shifts from selling more product, to securing inclusion in shrinking baskets.  

Beverage brands should conduct a portfolio audit through an economic lens to ensure margin resilience without a dependency on volume. This is not simply rationalization for its own sake: it is about identifying where to place fewer, bigger bets in a market where SKUs consume organizational energy. As demand for more units declines, brands need to ask: 

• Where does the product rely disproportionately on impulse mechanics?  

• Where have SKUs changed as consumers are actively moderating, and importantly which SKUs have remained the same? 

• Will profitability sustain if people are buying fewer units? 

Although reformulation might be necessary, this alone is not the strategy. The priority needs to be to refocus growth from selling more to securing selection in fewer, more intentional moments. 

2. Rebuild credibility: make trust a commercial asset

GLP-1 drugs introduce consequences into consumption. With a large proportion of users reporting side effects, including nausea, bloating etc., product tolerance becomes a deciding factor. 

This shifts brand equity from emotional familiarity to physiological compatibility. Reassurance becomes more valuable than seduction. 

In this environment, ambiguity becomes risk, which becomes unappealing. Clear ingredients lists, digestible claims and straightforward messaging promote product confidence. Brands should elevate transparency to a strategic priority in order to differentiate themselves from competitors. 

Partnership strategies should evolve accordingly. Credibility built through qualified experts, nutrition professionals or recognized performance standards will carry more weight than trend-driven influencer endorsements. 

The brands that win will not be those that shout the loudest, but those that feel safest, clearest and most compatible with consumer goals. 

3. Compete on context, and redesign how decisions get made

As GLP-1 users become less impulse-driven, the competitive battleground shifts. Success is no longer primarily about shelf visibility – it is about contextual relevance. 

Traditional retail mechanics rely on impulse, but in a lower-dopamine, lower-frequency environment, these tactics generate awareness but are decreasingly likely to convert to sales. 

Growth will depend on showing up in the right moment and embedding within intentional occasions where purpose exists. This requires deliberate reallocation of investment. Instead of disproportionately spending on in-store impulse mechanics, brands should identify and aim to own consumption territories, i.e.: 

• Hydration brands in performance and fitness environments 

• Low and no-alcohol brands/variants in moderation-focused social occasions 

• Functional drinks in wellness arenas 

• Portion-controlled formats in premium settings 

Distribution strategy becomes as important as product strategy. The question shifts from ‘how do we attract attention?’ to ‘where does this product genuinely belong, and how quickly can we test whether that belief is true?’ 

This is where the operational challenge becomes critical. Pilot Lite’s perspective is that corporates cannot afford to wait for perfect certainty: product, packaging, channel, messaging and supply chain assumptions all need to be tested together, in market, with enough speed to learn before the category is redefined for someone else. For large beverage businesses, that means supply chain agility is no longer a back-office enabler, but a critical growth capability.  

Smaller packaging sizes, new formats, functional claims and alternative routes to market all place pressure on manufacturing, procurement, governance and partner onboarding. A strategy that requires 18 months of internal process before it reaches real consumers it not a strategy for a market moving this quickly. The organizations that win will be those that can reduce the time between learning and launching – turning insight into in-market execution in weeks, not months.  

That makes this as much a leadership and culture question as a category question. CPG organizations were historically built for reliability, consistency and scale; these strengths still matter, but they can become constraints when the market requires autonomy, calculated risk-taking and faster cross-functional decisions. The task is not to remove governance, but to redesign it so that teams can test, learn and adapt.  

Conclusion

GLP-1 drugs are not simply a health trend. They are altering consumer behaviors by entirely rewriting appetite, impulse and reward. 

Beverage brands that continue to push for volume, visibility and excitement may struggle to create desired returns. Those that focus on relevance, credibility, functional fit and speed of execution will be better positioned to withstand the change and grow. 

The challenge is not to fight moderation. It is to build alongside it, and to move quickly enough that insights become decisions, decisions becomes tests and tests translate to scalable growth all before the market moves on.